Virtual Library
Start Your Search
B. Lin
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-071 - Efficacy of Thoracic Radiotherapy in Oligometastatic Non-Small-Cell Lung Cancer Harboring Wild-Type EGFR After First-Line Chemotherapy (ID 9650)
09:00 - 09:00 | Author(s): B. Lin
- Abstract
Background:
Evidence from retrospective and small prospective trials suggested that local therapy might be beneficial for patients with oligometastatic non-small-cell lung cancer (NSCLC). The purpose of this study is to analyze the efficacy of thoracic radiotherapy in oligometastatic NSCLC patients harboring wild-type EGFR that did not progress after first-line chemotherapy in Asian population.
Method:
We retrospectively reviewed 181 stage IV NSCLC patients harboring wild-type EGFR with three or fewer metastatic lesions after first-line chemotherapy with an Eastern Cooperative Oncology Group(ECOG) performance status(PS) score of 2 or less. All the patients treated with first-line therapy of four to six cycles of platinum doublet therapy and did not progress. Patients were classified into two regimens: 89 patients received thoracic radiotherapy (arm A) with volumetric modulated arc therapy (VMAT) technology, 92 patients received maintenance treatment or observation only (arm B). Maintenance treatment used only one chemotherapy drug including gemcitabine or pemetrexed or docetaxel, and observation was defined as close surveillance without cytotoxic treatment. The progression-free survival (PFS) was defined as the interval from the date of treatment to the earliest date of disease progression or death. The overall survival (OS) was defined as the interval from the date of treatment to the date of death. PFS and OS were estimated by the Kaplan-Meier method and were compared by the log-rank test.
Result:
The median PFS of the thoracic radiotherapy arm was significantly longer than that of the maintenance treatment arm (7.5 vs. 4.3 months, p = 0.006). The median OS of the thoracic radiotherapy arm also slightly longer than that of maintenance treatment or observation arm (13.0 vs. 10.0 months, p=0.031). Multivariate analysis indicated that thoracic radiotherapy were independent predictors of PFS. Thoracic radiotherapy, ECOG PS (0-1) ,histology adenocarcinoma and no brain metastasis were correlated with longer OS.
Conclusion:
The thoracic radiotherapy could improve PFS and OS in oligometastatic unresectable NSCLC patients harboring wild-type EGFR that did not progress after first-line chemotherapy.
